A single 150 mg dose of the ingredient was found to stimulate production of ATP in the blood by 40% over baseline levels at 60 minutes and 28% over baseline levels at 120 minutes, according to findings published in The Journal of Aging Research & Clinical Practice.
As part of the second study, a muscle biopsy was performed on one of the study subjects before, and 60 and 120 minutes after, ingestion of elevATP. The results showed that the intramuscular ATP levels increased significantly, with reported levels substantially higher than even the increases of ATP measured in whole blood.
“We have thus confirmed the ability of elevATP to increase ATP levels in whole blood. We have further shown that elevATP does not increase ATP levels in plasma,” wrote the researchers, led by Tania Reyes-Izquierdo from Applied BioClinical Inc. in Irvine, CA.
“A clinical case experiment demonstrated that ingestion of a single dose of elevATP resulted in a significant increase in intramuscular ATP under resting conditions. This result suggests that ingestion of elevATP may increase ATP level in other tissues. Further clinical testing is justified and is needed to confirm this preliminary result.
“Investigating whether elevATP may improve muscle performance and endurance in young and aged individuals and such experimentation is also justified and is currently in preparation.”
The study was funded by Futureceuticals.
‘New opportunity’
The study’s findings were welcomed by John Hunter, Executive Vice President of FutureCeuticals, as taking the company’s years of, “exciting discovery and clinical work on elevATP to a new level.
“Healthy mitochondrial function and the body's ability to produce endogenous ATP are vital for healthy aging and optimal performance. The combined gold-standard clinical results from two peer-reviewed published studies are exciting developments for product formulators working in the categories of healthy aging and sports performance.
“Regarding the latter, considering the recent substantial scrutiny on the usual ingredients in energy drinks, elevATP represents a new opportunity to build a platform on a safe ingredient backed by clinical science.”
Study details
Researchers from Applied BioClinical and Futureceuticals recruited 20 healthy adults who fasted and were then given a single dose of the elevATP-containing supplement or placebo in a cross-over design. Blood samples were taken immediately prior to ingestion and again 60 and 120 minutes later.
Results showed that whole blood levels of ATP were increased in elevATP group by 40% after 60 minutes and by 28% after 120 min versus values taken prior to supplementation. Plasma levels of ATP did not change.
One subject consented to a muscle biopsy, which showed that intramuscular ATP levels increased significantly at 60 and 120 minutes after ingestion of elevATP. The levels were greater than those observed for the whole blood.
“Additional work in a larger number of volunteers is in preparation to confirm the stimulatory effect of elevATP on intramuscular ATP levels in resting subjects,” they added.
Source: The Journal of Aging Research & Clinical Practice
Number 04, December 2013
“The effect of elevATP on whole blood ATP levels: A single dose, crossover clinical study”
Authors: T. Reyes-Izquierdo, C. Shu, R. Argumedo, B. Nemzer, Z. Pietrzkowski